EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials

Brett King iD, Arash Mostaghimi, Yutaka Shimomura, Abraham Zlotogorski, Gwang-Seong Choi, Ulrike Blume-Peytavi, Thierry Passeron, Katrin Holzwarth, Yves Dutronc, Jill McCollam, Fan Emily Yang, Sarah Stanley und 2 weitere

British Journal of Dermatology · 2023

DOI: 10.1093/bjd/ljac059 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Dermatology, 2023. Verfasst von Brett King und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Yale School of Medicine, New Haven, CT, USA. Hauptthemen laut MEDLINE: Alopecia Areata, Janus Kinase Inhibitors. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Baricitinib, an oral, selective, reversible Janus kinase (JAK)1/JAK2 inhibitor, is an approved treatment for adults with severe alopecia areata (AA) in the USA, European Union and Japan.

Objectives

To report safety data for baricitinib in patients with severe AA from two clinical trials including long-term extension periods.

Methods

This analysis includes pooled patient-level safety data from two trials, an adaptive phase II/III trial (BRAVE-AA1) and a phase III trial (BRAVE-AA2) (ClinicalTrials.gov, NCT03570749 and NCT03899259). Data are reported in three datasets: (i) the placebo-controlled dataset (up to week 36): baricitinib 2 mg and 4 mg vs. placebo; (ii) the extended dataset (up to the data cutoff): patients remaining on continuous treatment with baricitinib 2 mg or 4 mg from baseline; and (iii) the all-baricitinib dataset (all-BARI, up to the data cutoff): all patients receiving any dose of baricitinib at any time during the trials. Safety outcomes include treatment-emergent adverse events (TEAEs), adverse events of special interest and abnormal laboratory changes. Proportions of patients with events and incidence rates (IR) were calculated.

Results

Data were collected for 1303 patients who were given baricitinib, reflecting 1868 patient-years of exposure (median 532 days). The most frequently reported TEAEs during the placebo-controlled period (based on the baricitinib 4-mg group) were upper respiratory tract infection, nasopharyngitis, headache, acne and elevated blood creatine phosphokinase (CPK). During the placebo-controlled period, the frequency of acne was higher with baricitinib than placebo, and elevated CPK was higher with baricitinib 4 mg than placebo and baricitinib 2 mg. In all-BARI, the IR of serious infections was low (n = 16, IR 0.8). There was one opportunistic infection (IR 0.1), and 34 cases of herpes zoster (IR 1.8). There was one positively adjudicated major adverse cardiovascular event (myocardial infarction) (IR 0.1), one pulmonary embolism (IR 0.1), three malignancies other than nonmelanoma skin cancer (IR 0.2) and one gastrointestinal perforation (IR 0.1). No deaths were reported.

Conclusions

This integrated safety analysis in patients with severe AA is consistent with the overall safety profile of baricitinib. Some differences with atopic dermatitis were noted that may be attributable to the disease characteristics of AA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alopecia AreataJanus Kinase InhibitorsHumansAdultTreatment OutcomeRandomized Controlled Trials as TopicDouble-Blind MethodAzetidinesPurinesPyrazolesSulfonamides

Substanzen

Janus Kinase InhibitorsbaricitinibAzetidinesPurinesPyrazolesSulfonamides

Autor:innen und Institutionen

  • Department of Dermatology, Yale School of Medicine, New Haven, CT, USA.
  • Brigham and Women's Hospital, Boston, MA, USA.
  • Department of Dermatology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan.
  • Department of Dermatology, Hadassah Medical Center, Hebrew University of Jerusalem, The Faculty of Medicine, Jerusalem, Israel.
  • Department of Dermatology, Inha University School of Medicine, Incheon, South Korea.
  • Department of Dermatology, Venereology and Allergology, Charité-Universitaetsmedizin, Berlin.

ORCID-Profile: Brett King

Förderung

  • Eli Lilly and Company

Zitieren

APA

King, B., Mostaghimi, A., Shimomura, Y., Zlotogorski, A., Choi, G. S., Blume-Peytavi, U., Passeron, T., Holzwarth, K., Dutronc, Y., McCollam, J., Yang, F. E., Stanley, S., Wu, W. S., & Sinclair, R. (2023). Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljac059

Vancouver

King B, Mostaghimi A, Shimomura Y, Zlotogorski A, Choi GS, Blume-Peytavi U, et al. Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials. British Journal of Dermatology. 2023. doi:10.1093/bjd/ljac059

BibTeX
@article{King2023,
  author = {King, Brett and Mostaghimi, Arash and Shimomura, Yutaka and Zlotogorski, Abraham and Choi, Gwang-Seong and Blume-Peytavi, Ulrike and Passeron, Thierry and Holzwarth, Katrin and Dutronc, Yves and McCollam, Jill and Yang, Fan Emily and Stanley, Sarah and Wu, Wen-Shuo and Sinclair, Rodney},
  title = {Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials},
  journal = {British Journal of Dermatology},
  year = {2023},
  doi = {10.1093/bjd/ljac059}
}
Kostenlos starten →